Most diagnoses of ulcerative colitis are in men between the ages of 15 and 35. The disease course for ASUC can be harder to predict, but it commonly appears between ages 34 and 48.

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that occurs in ∼20% of patients with ulcerative colitis. Here, the authors provide an overview of ASUC from ...

The American College of Gastroenterology has released updated guidelines on the diagnosis and management of patients with mild and moderate to severe ulcerative colitis.“The guidelines are ...

Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol . Published online January 22, 2024. doi:10.14309/ajg ...

In an intention-to-treat analysis involving 149 patients with ASUC, no significant difference was seen between the number of patients who responded to treatment by 7 days using maximal mesalamine ...

Among them, 26.6% were corticosteroid-refractory, and 75.7% met the criteria for acute severe ulcerative colitis (ASUC). Most studies investigated EEN as an adjunctive therapy to standard care, ...

Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design -- this ...

Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research ...

ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate ...

Using an accelerated induction therapy of Remicade for a rescue treatment of acute severe ulcerative colitis did not help improve colectomy rates compared with using a standard therapy, according ...

ST. PAUL, Minn., June 25, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced ...